Valuation: NFL Biosciences

Market Cap 7.32M 8.2M 6.83M 6.19M 11.65M 778M 11.74M 81.79M 32.02M 405M 30.79M 30.12M 1.3B P/E 2024
-9.56x
P/E 2025 -4.62x
Enterprise Value 5.71M 6.39M 5.32M 4.82M 9.07M 606M 9.14M 63.7M 24.94M 315M 23.99M 23.46M 1.01B EV / Sales 2024
370,592x
EV / Sales 2025 70,790x
Free-Float
85.79%
Yield 2024 *
-
Yield 2025 -
1 day-6.77%
1 week-11.62%
Current month-16.23%
1 month-31.19%
3 months-33.56%
6 months-47.17%
Current year-50.93%
1 week 0.56
Extreme 0.56
0.65
1 month 0.56
Extreme 0.56
0.82
Current year 0.56
Extreme 0.56
1.85
1 year 0.56
Extreme 0.56
1.85
3 years 0.56
Extreme 0.56
3.28
5 years 0.55
Extreme 0.548
4.29
10 years 0.55
Extreme 0.548
5
Manager TitleAgeSince
Chief Executive Officer - 17/10/2024
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 27/02/2023
Chairman - 17/10/2024
Director/Board Member - 19/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.77%-11.62%-54.49%-61.31% 8.78M
-0.32%-5.97%+57.78%+74.48% 70.65B
-1.99%-13.92%+3.01%+51.60% 51.22B
-1.32%-1.70%+6.99%+35.47% 48.04B
-0.58%+0.27%+27.93%+30.76% 43.16B
-2.84%-5.72%+286.54%+530.02% 41.57B
-0.38%-3.78%+6.74%+95.25% 39.84B
-0.39%-1.48%+10.41%+43.19% 30.87B
-1.07%-10.58%+46.28%+3.47% 27.53B
-7.13%-7.02%-12.99%-14.07% 24.08B
Average -2.28%-5.46%+37.82%+78.89% 37.7B
Weighted average by Cap. -1.48%-4.99%+51.04%+100.42%

Financials

2024 2025
Net sales 46 51.49 42.88 38.87 73.16 4.89K 73.73 513.63 201.07 2.54K 193.39 189.15 8.16K 188 210.46 175.23 158.87 298.98 19.98K 301.33 2.1K 821.77 10.39K 790.39 773.05 33.34K
Net income -2.08M -2.33M -1.94M -1.76M -3.31M -221M -3.34M -23.23M -9.1M -115M -8.75M -8.56M -369M -3.32M -3.71M -3.09M -2.8M -5.28M -353M -5.32M -37.05M -14.5M -183M -13.95M -13.64M -588M
Net Debt -2.07M -2.32M -1.93M -1.75M -3.3M -220M -3.32M -23.14M -9.06M -115M -8.71M -8.52M -368M -1.62M -1.81M -1.51M -1.37M -2.58M -172M -2.6M -18.08M -7.08M -89.49M -6.81M -6.66M -287M
Projected Income Statement - Annual - NFL Biosciences
Logo NFL Biosciences
NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).
Employees
4
Date Price Change Volume
13/10/26 EUR 0.5780 -6.77% 62,851
12/10/26 EUR 0.6200 0.00% 4,683
09/10/26 EUR 0.6200 -2.97% 41,418
08/10/26 EUR 0.6390 -3.18% 39,296
07/10/26 EUR 0.6600 +0.92% 27,577

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NFL Biosciences
  1. Stock Market
  2. Stocks
  3. ALNFL Stock